You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
萬泰生物(603392.SH):鼻噴流感病毒載體新冠肺炎疫苗啟動臨牀試驗
格隆匯 09-09 16:55

格隆匯9月9日丨萬泰生物(603392.SH)公佈,公司與廈門大學、香港大學合作研發的鼻噴流感病毒載體新冠肺炎疫苗近日獲得國家藥品監督管理局臨牀試驗申請受理通知書(受理號:CXSL2000250國)及臨牀試驗批件(批件號:2020L00039),同意本品進行臨牀試驗,該批件有效期為12個月。根據臨牀試驗批件的要求,公司已啟動I期臨牀研究。一期臨牀的主要目的是評估新冠疫苗的安全性,並探索其免疫原性。

截至目前,境內外尚無新冠疫苗正式上市。世界多個國家正在開展新冠疫苗的研發工作,目前主流的有五條技術路線在開展相關研發工作。中國境內已經公開的有中生集團、康希諾、科興生物、智飛生物、復星醫藥等多家公司共計10個疫苗進入臨牀試驗階段。截至本公告日,現階段公司針對該疫苗的研發投入為人民幣525.44萬元(未經審計)。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account